BACKGROUND: High dose chemotherapy followed by autologous stem cell transplant is currently used for the treatment of @entity1 with advanced @entity1582 . However, there are no reports of the results of this treatment modality in Indian @entity1 . METHODS: Fifty @entity1 with advanced @entity1582 underwent treatment with high dose melphalan followed by autologous stem cell transplant (bone marrow: 7; peripheral blood stem cells: 43). The @entity1 ' ages ranged from 26 to 65 years (median: 52 years) and 35 were @entity1 . All @entity1 had received chemotherapy initially with a mean of 9.4 cycles (range: 1-36). Thirty @entity1 had evidence of chemosensitive disease at the time of transplant. The mean interval from diagnosis to transplant was 17.5 months (range: 3-129 months) and the median number of mononuclear cells infused was 4.86 x 10(8) per kg (range: 2-10.48). RESULTS: Post-transplant, 43 of 50 @entity1 engrafted. The median number of days to engraftment (absolute neutrophil count > 500/cmm) was 12 (range: 9-24) and to achieve platelet transfusion independence (> 20,000/cmm) was 13 (range: 8-36). Seven @entity1 died prior to engraftment. @entity3136 was the major non-haematological @entity137 . Excluding the 4 @entity1 who had complete response prior to the transplant and continued in the same status post-transplant, 31/46 @entity1 (67%) responded; complete response was achieved in 25 (54%) and partial response in 6 (13%). @entity1 with chemosensitive disease had higher rates of complete response; 20 of 26 @entity1 with partial response at transplant achieved complete response compared to 5 of 20 @entity1 with persistent/refractory disease (p < 0.01). Currently, 34 of 50 (68%) @entity1 are alive, 17 (34%) disease-free, 6 with disease are on salvage therapy, 11 (22%) with positive monoclonal protein but asymptomatic are under observation. Nine (18%) @entity1 have died; 8 due to progressive disease and 1 of an unrelated cause. The median follow up for the entire group is 26 months (range: 1-144 months). The Kaplan-Meier probability of overall and progression-free survival for the whole group at 30 months is 62% +/- 8.11% (SE) and 42% +/- 9.54% (SE), respectively. A haemoglobin level < or = 10 g/dl (p < 0.003) affected the survival adversely. @entity66 (p < 0.008) at transplant and complete response post-transplant (p < 0.0001) were associated with significantly longer survival. CONCLUSION: High dose melphalan followed by autologous stem cell transplantation is an effective treatment for @entity1 with advanced @entity1582 and achievement of complete response is associated with improved survival.

High dose chemotherapy followed by autologous haemopoietic stem cell transplant in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3136 :: ('MESH:D013280', 'Disease') :: ['Grade III-IV oral mucositis'] @entity66 :: ('MESH:D004194', 'Disease') :: ['Chemosensitive disease'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma']
@entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']
